[How to increase the adherence to treatment of patients with arterial hypertension and dyslipidemia: focus on fixed combination of amlodipine and atorvastatin].
The article is devoted to the problem of treatment patients with arterial hypertension and dyslipidemia. Questions of adherence to antihypertensive and lipid lowering therapy are discussed. Effects of first fixed combination amlodopine and atorvastatin, which deals with more than one risk factor, are analyzed.
Lopatin
Iu M
IuM
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D017311:Amlodipine / Q000494:pharmacology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000924:Anticholesteremic Agents / Q000494:pharmacology; D000959:Antihypertensive Agents / Q000494:pharmacology; D000069059:Atorvastatin; D002121:Calcium Channel Blockers / Q000494:pharmacology; D004232:Diuretics / Q000494:pharmacology; D004338:Drug Combinations; D016903:Drug Monitoring; D004357:Drug Synergism; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006331:Heart Diseases / Q000209:etiology / Q000401:mortality; D006538:Heptanoic Acids / Q000494:pharmacology; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D010349:Patient Compliance; D011758:Pyrroles / Q000494:pharmacology; D012307:Risk Factors
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000924:Anticholesteremic Agents; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics; D004338:Drug Combinations; D006538:Heptanoic Acids; D011758:Pyrroles; D017311:Amlodipine; D000069059:Atorvastatin